Karine Le Malicot

7PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.

David Tougeron, Christophe Louvet, Jérôme Desramé

|Sep 05, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Emeric Boisteau, Laetitia Dahan, Nicolas Williet

|Jun 26, 2024
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Elodie Martin, Karine Le Malicot, Catherine Guérin-Charbonnel

|Apr 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).

Jean-Louis Legoux, Roger Faroux, Nicolas Barrière

|Mar 15, 2022
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.

Clémence Canton, Olayidé Boussari, Mathieu Boulin

|Jul 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.

Laetitia Dahan, Nicolas Williet, Karine Le Malicot

Pageof 2

Frequent Collaborators

3 joint publications

Thomas Aparicio

3 joint publications

Come Lepage

3 joint publications

Laetitia Dahan

2 joint publications

Julien Taieb